Status:
RECRUITING
Acute Consequences of Glucocorticoid Secretion in Overweight and Obese Individuals During Maximum Calorie Intake
Lead Sponsor:
Eleonora Seelig
Conditions:
Glucocorticoids
Overweight and Obesity
Eligibility:
MALE
18-50 years
Phase:
NA
Brief Summary
The investigator aim to understand whether food-induced glucocorticoids influence fat mass in overweight and obese people. In a randomized, cross-over study, 23 overweight and obese volunteers will r...
Detailed Description
Obesity is one of the most serious health problems of the 21st century, and new therapies are urgently needed. Glucocorticoids (GCs) increase with acute food intake. Several clinical studies have fou...
Eligibility Criteria
Inclusion
- Males aged 18 to 50 years
- BMI≥ 25 kg/m² with a stable weight within past three months before study initiation
Exclusion
- Any severe acute or chronic disease, including diabetes mellitus type 2
- Intake of GLP-1 agonists or hormone therapy
- Hypercortisolism
- Casual smoking (more than 6 cigarettes per day)
- Frequent, heavy alcohol consumption (more than 30g/day)
- Frequent, heavy caffeine consumption (more than 4 caffeinated drinks/day)
- Regular physical exercise (more than 4hrs per week)
- Shift work
- Participation in an investigational drug trial within the past two months
- Intake of any steroid-containing drugs, including topical steroids and inhalers, within 4 weeks of the study initiation
- Known allergy to metyrapone
- Inability or unwillingness to provide informed consent
Key Trial Info
Start Date :
September 1 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2026
Estimated Enrollment :
23 Patients enrolled
Trial Details
Trial ID
NCT06556277
Start Date
September 1 2024
End Date
July 1 2026
Last Update
April 16 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital Basel
Basel, Canton of Basel-City, Switzerland, 4031